Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $212.5 million.

  • Beam Therapeutics' Non-Current Assets fell 588.89% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $873.2 million, marking a year-over-year decrease of 753.99%. This contributed to the annual value of $225.7 million for FY2024, which is 924.76% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Non-Current Assets is $212.5 million, which was down 588.89% from $215.7 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Non-Current Assets peaked at $259.1 million during Q2 2023, and registered a low of $178.7 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $225.8 million (2024), whereas its average is $227.9 million.
  • As far as peak fluctuations go, Beam Therapeutics' Non-Current Assets soared by 23015.84% in 2021, and later tumbled by 1052.02% in 2024.
  • Beam Therapeutics' Non-Current Assets (Quarter) stood at $201.4 million in 2021, then grew by 23.52% to $248.8 million in 2022, then fell by 0.06% to $248.7 million in 2023, then fell by 9.25% to $225.7 million in 2024, then dropped by 5.82% to $212.5 million in 2025.
  • Its Non-Current Assets was $212.5 million in Q3 2025, compared to $215.7 million in Q2 2025 and $219.3 million in Q1 2025.